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ABSTRACT Hereditary deficiency of the macromolecular
Factor VIII complex results in classic von Willebrand disease in
man and animals, a bleeder state characterized by loss ofthe mul-
tiple biologic activities associated with the Factor VIII complex,
including the platelet-aggregating von Willebrand factor. The
bleeding time is also long. Venom coagglutinin, a Bothrops factor
that causes platelet aggregation in vitro, depletes the plasma of
its von Willebrand factor.' The rate of platelet aggregation is a
function of the amount of the coagglutinin present. Based on this
observation, a sensitive and quantitative assay for the venom coag-
glutinin was developed. We administered the purified Bothrops
factor to normal pigs and dogs and induced a von Willebrand syn-
drome similar to the inherited disease. The plasma von Wille-
brand factor was severely depleted; the antihemophiic factor and
the Factor VIII-related antigen were not depleted as much. The
bleeding time was normal. During the induction phase of the syn-
drome, transient thrombocytopenia with a long bleeding time oc-
curred. The pig was less sensitive than the dog to the effect of coag-
glutinin. The severity of the syndrome is determined by the
amount of venom coagglutinin administered. It is suggested that
the syndrome could be induced in any mammalian species because
the plasma of all mammals tested in vitro is sensitive to the venom
factor. This model provides another avenue for the study of the
heterogeneity of the Factor VIII complex and the pathophysiology
of its components.
The discovery of a Bothrops venom factor, venom coagglutinin
(VCA), has provided a new probe for the study of plasma von
Willebrand factor (vWF) (1). vWF is so named because it is ab-
sent or depleted in von Willebrand's disease (vWD), an auto-
somally inherited bleeding disorder. Of the multiple abnor-
malities in vWD, a lack of the platelet aggregating vWF and a
prolonged bleeding time are most conspicuous. VCA appears
to "activate" plasma vWF, following which platelet aggregation
occurs. VCA has been uniquely valuable in providing a pro-
cedure for determination ofplasma vWF levels in both man and
animals and for measuring variations in this factor (1, 2). During
the course of this platelet-aggregating reaction with VCA in
vitro, the vWF was found to be depleted, leaving little or no
residual activity in the plasma. This finding suggested that the
administration ofVCA in vivo could produce the pathophysio-
logical counterpart of inherited vWD. However, a difficulty in
testing this hypothesis was the lack of an assay for VCA. It had
been observed that the rate of the vWF-dependent platelet
aggregation was determined by the amount ofVCA present (3).
Further study ofthis relationship revealed that, within a certain
range of macroscopic platelet aggregation times, the rate of the
reaction was both a sensitive and a quantitative function ofVCA
concentration. A unit of VCA could be defined. The bioassay
reported here appears to provide a reliable index for determin-
ing the potency ofVCA preparations. With this procedure, we
were able to study the dose-response relationship in animals
given VCA.
In the animals studied, it was found that a von Willebrand-
like disorder could be quickly produced with appropriate doses
ofVCA. The disorder was characterized by a depletion ofplasma
vWF and was similar in its characteristics to the phenotypic
manifestations ofone ofthe variants ofvWD in man (4). Because
of its acquired nature, the animal disorder is designated von
Willebrand syndrome (vWS) rather than von Willebrand
disease.
MATERIAL AND METHODS
Experimental Animals. Normal pigs and normal dogs ofboth
sexes were used. The pigs, ages 2-3 mo, weighed 11.5-24 kg;
the dogs, ages 4.5 mo to >5 yr, weighed 8.5-26.5 kg. The an-
imals were from controlled breedings of stock maintained at the
University's Francis Owen Blood Research Laboratory.
Preparation of VCA. VCA for the infusion experiments was
prepared from the crude dried venom of B. jararaca (Sigma)
by a chromatographic procedure (1) using a DEAE-cellulose
column and elution with high-molarity NaCl. VCA fractions
were made approximately isotonic (equivalent to 0. 154 M NaCl)
by dilution or dialysis and were further diluted with saline
usually containing porcine or canine albumin (0.1%) (Sigma) for
pig and dog experiments, respectively. The final preparations
contained 75 units of VCA per ml and had no thrombin-like
enzyme activity as judged by no clotting of a human fibrinogen
(Kabi) solution in 120 min.
Infusion Studies. The general procedure for infusions has
been described (5). VCA was injected intravenously into the
cephalic vein of the pig and into the jugular vein of the dog at
the rate of 1-4 ml/min. Blood samples for analysis were ob-
tained from each animal once or twice on separate days prior
to infusion, immediately before infusion, and at 20 min, 1, 2,
4, 8, 12, 24, 48, and 72 hr, and occasionally at 120 hr after
infusion.
Assays for Factor VIII Complex Activities. vWF assays were
performed by the VCA method with the macroscopic aggre-
gation test procedure (3). For these studies, the test mixture
contained equal parts of the following: 0.084 M imidazole-buff-
ered saline, pH 7.35; citrated plasma, serially diluted with
buffer; VCA; and dog platelets, formaldehyde-fixed and usually
lyophilized, 800,000/mm3 (6). For pig plasmas, supplementary
vWF determinations were made in some experiments with the
macroscopic platelet aggregating factor (PAF) procedure (5) and
with the macroscopic ristocetin test using lyophilized platelets
(3). Plasma inhibitors ofvWF were tested for by a modification
Abbreviations: VCA, venom coagglutinin; vWF, von Willebrand factor;
vWD, von Willebrand disease; vWS, von Willebrand syndrome; AHF,
antihemophilic factor; PAF, platelet aggregating factor.
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of the method of Brinkhous and Culp (7). Antihemophilic factor
(AHF; Factor VIII:C) assays were performed by a modification
of the partial thromboplastin time procedure (8) using canine
hemophilic substrate; the unactivated test was used for pig
plasma and the kaolin-activated procedure was used for dog
plasma. Factor VIII-related antigen (VIIIR:Ag) in pig plasma
was assayed as described (5). For the above three tests, citrated
plasmas were stored at -700C until tested. Reference citrated
pig and dog plasmas, assigned a value of 1 unit/ml or 100% for
each of the above variables, consisted of a plasma pool from
three or four normal animals. Saline bleeding times were de-
termined by the method of Mertz (9) at the same time intervals
as indicated for blood sampling.
Platelet counts were determined on freshly collected venous
blood by using the Unopette microcollection system (no. 5855,
Becton Dickinson, Rutherford, NJ) according to the manufac-
turer's directions.
RESULTS
Depletion of Plasma vWF in Vitro with VCA. The plasma
vWF activity was largely eliminated from pig plasma within a
few minutes by the action ofVCA in the presence of platelets
(Table 1). Only traces of vWF remained in the supernatant
plasma after removal of the aggregated platelets. This was also
true for dog plasma. The VCA-mediated reaction appeared to
be much more effective in depleting the plasma of vWF than
were two other vWF-dependent reactions, aggregation with
ristocetin and with PAF. When ristocetin (2 mg/ml) was sub-
stituted for VCA in the reaction mixture of test 1 (Table 1), re-
sidual vWF was 25%. In the PAF reaction, with lyophilized
human platelets substituted for canine platelets and VCA omit-
ted from the reaction mixture, residual vWF was 66%, a value
in good agreement with a previous study with bovine plasma
(10). Repeated stepwise platelet aggregation in both the risto-
cetin and the PAF reaction was required to decrease the vWF
further, in contrast to the nearly complete depletion of vWF
in the one-step procedure with VCA. The VWF in dog plasma
is refractory to the ristocetin and PAF procedures (11).
Bioassay of VCA Activity. The bioassay ofVCA is based on
the observation that the rate of platelet aggregation under stan-
dard conditions with a constant amount of plasma vWF is de-
pendent on the concentration ofVCA (Fig. 1). On the arithmetic
plot, the segment of the curve between 12 and 16 sec ap-
proaches linearity and was selected for measuring relative po-
tency of VCA solutions. One unit of VCA is defined as that
amount in 1 ml which causes a platelet aggregation time of 14
sec in a four-part standard test system, one part ofwhich is VCA.
From the data of Fig. 1 Inset, Table 2 was developed, which
indicates the aggregation times resulting with varying VCA con-
centrations in the range 0.75-1.35 units/ml.
Table 1. In vitro depletion ofvWF in pig plasma with VCA
Test system components Residual vWF,
Test Plasma Platelets VCA %
1 + + + <5
2 + + 0 100
3 + 0 + 100
vWF values are expressed as percentage of homologous reference
plasma. In test 1, equal parts ofplasma, buffer, fixed lyophilized canine
platelets (1,600,000/mm3), and VCA (50 units/ml) were mixed. Buffer
was substituted for the omitted reagent in tests 2 and 3. After incu-
bation and agitation for 2 min, samples were centrifuged and residual
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FIG. 1. Derivation of a VCA unit: Relationship ofVCA concentra-
tion to platelet aggregation time. Test system consisted of equal parts
of: (i) normal human plasma, reference pool stored at -70°C, desig-
nated as 1 unit ofvWF per ml; (ii) buffer; (iii) lyophilized human plate-
lets, a reference lot stored at -70°C and reconstituted, 800,000/mm3;
and (iv) VCA solution. (Inset) Logarithmic replot of data in the range
9-16 sec, with conversion ofVCA concentration to units/ml: 1 unit of
VCA per/ml is equivalent to aggregation time = 14 sec.
An illustrative example of bioassay of an unknown prepara-
tion for VCA potency follows. The VCA solution was diluted
such that at least two of the diluted samples caused aggregation
in the range 12-16 sec (Table 2). The samples diluted 1:128 and
1:175 met this criterion with aggregation times of 13.0 and 15.5
sec, respectively (each an average of three replicate determi-
nations). These time values are equivalent to VCA concentra-
tions of 1.16 and 0.78 units/ml in the final test mixture. The
VCA value based on the 1:128 sample would be
128 (reciprocal of the initial dilution)
x 4 (reciprocal of 1:4 dilution in the test mixture)
X 1.16 (VCA in final test mixture from Table 2).
= 594 VCA units/ml
For the 1:175 sample, the value would be 546 units/ml, for a
mean of 570 units/ml.
Induced vWS. VCA in varying doses was administered to six
normal pigs and six normal dogs. In the pig, in a typical ex-
periment (Fig. 2A), the vWF activity decreased to <10% in the
first 2 hr after injection and reached a minimum of <5% at 8
hr. Severe reduction of plasma vWF persisted for 24 hr, and
then the vWF activity slowly returned to normal. At 48 hr, it
was 50% of normal, and at 120 hr it was approximately 90%.
When the vWF assays were also performed with the ristocetin
procedure and human platelets, comparable reduced levels of
plasma vWF were obtained at all time points.
Table 2. Derived conversion factors for bioassay ofVCA
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FIG. 2. Infusion of VCA into a normal pig (A) and a normal dog
(B). The pig (male; 13.2 kg; 2 mo old) received 300 units of VCA per
kg body weight. The dog (female; 26.4 kg; >5 yr old) received 86 units/
kg. The preinfusion values for vWF, AHF, and platelet count were
assigned a value of 100%, and the postinfusion values represent
changes from these baselines. Arrows represent times of VCA
administration.
In the normal dog (Fig. 2B), the response to the VCA infusion
was similar to that in the pig. A lower dose was administered,
86 units/kg compared to 300 units/kg in the pig. The vWF lev-
els were consistently .5% of normal for nearly 24 hr and then
returned to >90% at 72 hr postinfusion.
The bleeding time value at each postinfusion interval shown
in Fig. 2 was normal or nearly so in both the pig and the dog.
Even when the vWF activity was '5% at 4-12 hr in the pig and
at 2-24 hr in the dog, the bleeding time was not prolonged.
The platelet count after VCA infusion was depressed in both
animals. Recovery of the platelet count to about 75% of prein-
fusion values was noted at 12 hr in the pig and at 24 hr in the
dog.
AHF activity was also depressed in both species after injec-
tion ofVCA. The AHF activity in the pig reached a nadir of23%
of the preinfusion value at 8 hr, when the vWF activity was
<5%. The AHF level had recovered to >50% at 24 hr. In the
dog, the AHF level was lowest at 4 hr (36%) and had returned
to >50% of the preinfusion value by 8 hr. Factor VIII-related
antigen in the pig experiment was depressed moderately, as
follows: 100%, preinfusion value; 85%, 2 hr; 73%, 4 hr; 56%,
8 hr; 46%, 12 hr; 50%, 24 hr; and 56%, 72 hr. Test for inhibitors
ofvWF in the 8-hr plasma sample from the pig was negative.
The dose-response relationship between the amount ofVCA
given and the maximal vWF depression after the injection is
shown in Fig. 3. At equal VCA doses based on weight, there
was a greater depression ofvWF in the dog than in the pig. For
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FIG. 3. Response ofplasma vWF to infused VCA. Maximal depres-
sion of vWF after infusion in normal pigs (o) and normal dogs (e) is
plotted against VCA. The data points at 43 units/kg for the pig and
at 43, 86, and 150 units/kg for the dog each represent the average from
two experiments; remaining points represent single experiments.
to <5% but in the pig it was decreased to only 25%. Maximal
vWF reduction to <5% occurred in the pig only with a VCA
dose of 300 units/kg.
The initial response to VCA injections in normal pigs and
dogs was studied at 20 and 60 min. This time interval is des-
ignated as the induction period. Illustrative data are shown in
Table 3. In pigs given VCA doses of 150 and 300 units/kg, there
was an immediate and severe thrombocytopenia with a con-
comitant prolongation of the bleeding time to >15 min. With
limited recovery ofthe platelet count at the 60-min interval, the
bleeding time was only slightly prolonged. The bleeding time
value had returned to within normal limits at the 2-hr interval
(Fig. 2A). The thrombocytopenia was transient, being most
marked at 20 min with continual return to normal thereafter.
In contrast, vWF levels were just beginning to be depressed
at the 20-min interval, after which they progressively declined
to reach their lowest levels at 4-12 hr. In the dog, the greater
sensitivity to vWF depression with VCA was also evident in the
induction period. In both species, AHF during this time period
was much less affected than was either vWF or platelets. The
general well-being of the animals was maintained throughout
the experiments, with no overt effects being observed. There
were no hemorrhages.
DISCUSSION
An animal model for the vWS was induced in normal pigs and
dogs by the intravenous infusion of the venom cofactor VCA
which appears to cause activation and utilization of the plasma
vWF. The finding that VCA effectively depleted normal plasma
of its vWF activity in a one-step procedure (Table 1) led us to
the testing of VCA in vivo. The syndrome is similar in many
ways to inherited vWD in man and animals. In the fully de-
veloped induced syndrome, there was a severe deficiency of
plasma vWF with accompanying modest reductions in coagu-
lant Factor VIII (AHF) (Fig. 2) and Factor VIII-related antigen.
The syndrome persisted for approximately 24 hr, after which
the animals gradually returned to the preinjection state in 2-3
days. Because there were differences in the response ofanimals
to various lots ofVCA, the need for aprocedure for determining
relative potency ofVCA preparations became important. Thus,
a bioassay for VCA was developed.
Proc. Nad. Acad. Sci. USA 78 (1981)
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Table 3. Induction period ofvWS
VCA Platelet count, Bleeding time,
dose, VWF, % % min AHF, %
Animal units/kg 20 min 60 min 20 min 60 min 20 min 60 min 20 min 60 min
Pigs
1 8 99 100 84 84 N N 96 89
2 43 64 33 73 99 N N 91 70
3 86 76 67 28 84 N N 96 81
4 86 73 43 11 34 N N 119 83
1* 150 77 57 <1 4 >15 6 98 92
5 300 22 9 1 5 >15 7.5 40 43
Dogs
1 8 100 100 79 60 N N 107 91
2 43 98 32 5 10 8 9.5 98 91
2* 43 67 40 4 17 12.5 N 108 66
3 86 5 5 36 64 N N 60 56
4 150 s5 c5 4 27 >15 >15 88 87
4* 150 s5 -5 5 20 13.5 >15 60 60
The data shown as % are expressed in relation to preinfusion value = 100%. N, s5 min.
* Animals injected withVCA a second time within 4-9 days after first injection. Mean preinfusion platelet counts: pigs, 765,000/mm3; dogs, 430,000/
3mm .
The VCA bioassay is based on earlier observations made dur-
ing the development of the VCA test procedure for measuring
plasma vWF (3)-namely, that the rate of platelet aggregation
is a function of VCA concentration as well as of vWF concen-
tration. Hence, it was necessary to maintain a constant amount
ofVCA for the performance ofvWF assays. Conversely, in the
bioassay ofVCA, a constant amount ofvWF was maintained in
the test so that the aggregation times became a function of only
VCA concentration (Fig. 1). The segment of the curve relating
aggregation time to VCA concentration that approached linear-
ity was used for the definition ofa VCA unit and for the bioassay
procedure. On the basis of these observations, a value of 1 unit
ofVCA per ml was arbitrarily assigned to that final concentration
of VCA in the test mixture which caused an aggregation time
of 14 sec. For a given VCA preparation, the unitage value ap-
pears to be reproducible within about ± 10% on replicate de-
terminations. This reproducibility is comparable to that ob-
served with bioassays for most procoagulant factors, such as
AHF. The macroscopic aggregation time method was chosen
for the VCA assay rather than the aggregometry method (3)
because the former appeared to detect smaller differences in
VCA concentration. Table 2 provides factors for the determi-
nation of VCA units when there are minor deviations in the
platelet aggregation time from the 14 sec or 1 unit VCA equiv-
alent value. This bioassay method appears to be a quantitative
and useful procedure for determining VCA concentration.
The pathophysiologic responses of the pig and the dog to in-
fused VCA in the induction ofvWS were similar (Fig. 2). At 2-4
hr there was a profound depression of the platelet aggregating
vWF (<5%) which persisted for many hours. On the other
hand, the bleeding time values were within or near normal val-
ues. This dissociation between plasma vWF levels and bleeding
time values in the induced syndrome is in sharp contrast to their
concordance in classic homozygous vWD in man (4), swine (5),
and dogs (12), in which vWF is absent and bleeding time is in-
definitely prolonged. There have been other reports of a dis-
sociation of "bleeding-time factor" activity and vWF activity
after transfusion in severe vWD in humans (13) and in swine
(5). There are also reports of variant vWD with severely de-
creased vWF, moderately decreased AHF and Factor VIII-re-
lated antigen levels, and normal bleeding time (4), similar to
the vWS-related antigen induced with VCA. The antigen level
was depressed much less than in classic vWD, in which its value
typically corresponds to that of plasma vWF.
The most striking difference between pigs and dogs was in
the dose-response relationships. To produce the fully devel-
oped syndrome with depletedvWF in the pig, VCA at 300 units/
kg was needed, whereas in the dog, 86 units/kg, less than one-
third of the pig dose, was sufficient. The dose-response curves
(Fig. 3) demonstrate that the relative resistance of the pig to
VCA compared to the dog was evident in all VCA dosages
tested. Also illustrated in Fig. 3 is the fact that one can produce
vWS of any degree of severity by proper regulation of the dose
ofVCA. The milder syndrome induced with lower doses ofVCA
persisted for shorter periods of time than did the severe syn-
drome with the higher doses.
The constellation of abnormalities observed during the in-
duction period is different from that observed in the fully de-
veloped syndrome (Table 3). Thrombocytopenia occurred im-
mediately, with partial recovery already underway at 1 hr. If
the decrease in platelets was severe, the bleeding time was
prolonged in both species of animals, but this association was
not exact. One might have anticipated from the vWF depletion
experiments in vitro (Table 1) that in vivo the plasma vWF val-
ues after VCA administration would immediately be decreased
to their lowest levels, paralleling the decrease in platelets. This
was not the case. Consistently, the vWF level continued to
decline to its nadir in the 2-12 hr when the bleeding time anom-
aly had been corrected and the platelet count was approaching
normal levels. This delayed depletion of vWF suggests that
extravascular vWF stores may temporarily replete the plasma,
only to be consumed by the continued action of the VCA.
Acquired vWS in humans has been reported many times (14).
The pattern of Factor VIII activities is similar to that of severe
inherited vWD, with low levels of plasma vWF, Factor VIII-
related antigen, and AHF, with a long bleeding time. The syn-
drome usually develops as a complication ofsome other disease,
such as systemic lupus erythematosus or hematopoietic malig-
nancy. Many of the patients have a neutralizing antibody for
vWF and, rarely, for AHF also, similar to the antibody vWF-
inhibitor originally described in a multiply transfused homo-
zygous vWD patient (15, 16). Thus, these patients with an ac-
quired vWS appear to have an autoimmune disorder, very dif-
ferent from the VCA-induced vWS in pigs and dogs. The former
usually appears to be due to the inhibitor effect of an antibody
which neutralizes vWF, whereas the induced vWS appears to
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be based on a massive consumption or utilization ofvWF and,
to a lesser extent, of AHF and Factor VIII-related antigen. In
the stabilized state ofthe severe VCA-induced vWS, the bleed-
ing time is normal or very slightly prolonged, whereas in the
human acquired disease the bleeding time generally has been
greatly prolonged. No vWF inhibitor was found in the induced
severe syndrome as tested with a vWF activity neutralization
test (7). Some humans with vWS likewise appeared not to have
a neutralizing antibody (17). These patients could be analogous
to the syndrome described here in animals, possibly a triggered
vWF consumption induced by a released VCA-like factor during
the course of disease. Should this be the case, then acquired
vWS could be classified as either autoimmune usually withvWF
neutralization or as a vWF-consumption syndrome due to re-
lease of a (physiologic) factor analogous in its action to VCA,
comparable perhaps to diffuse intravascular coagulation in re-
lation to the procoagulant biologic system.
The vWS syndrome was developed in two selected animal
species because the plasmas of both were sensitive to VCA in
the assay ofvWF and were fully depleted ofvWF in the pres-
ence ofVCA and platelets. All plasmas ofwidely different mam-
malian species thus far tested (2) have likewise been sensitive
to the effects of VCA. It would thus seem likely that the vWS
could be produced in most mammalian species. Such animal
models should be valuable for the further study of the patho-
physiology and the nature of the functional and structural het-
erogeneities of the macromolecular Factor VIII complex.
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